Ibrexafungerp (MK-3118; MK3118; SCY078; SCY-078; Brexafemme) is a triterpenoid based glucan synthase inhibitor that has been approved in 2021 by FDA as an antifungal medication to treat vulvovaginal candidiasis (VVC), a vaginal yeast-mediated infection. It acts similarly to echinocandins by inhibiting (1→3)-β-D-glucan synthase, which is a key glucosyltransferase enzyme for the biosynthesis of β-(1,3)-D-glucan in the fungal cell wall, thus leading to fungicidal effects.

纯度：≥98%

CAS：1207753-03-4